TERN Group raises $33M to cut GCC's nine-month specialist hiring cycle with clinical AI

TERN Group closed a $33 million funding round in September 2025, backing a clinical AI workforce platform the company says is the first of its kind in the GCC. The raise puts TERN among the best-capitalized health-tech companies in the region, with Gulf investors committing serious capital to AI applied directly to clinical operations rather than hospital administration.

Why workforce, why now

The GCC's reliance on imported clinical talent is a structural fact and a recurring vulnerability. In the UAE, expatriate clinicians account for more than 80% of the licensed physician workforce, according to data published by the Dubai Health Authority (DHA). Recruitment cycles for specialists routinely run six to nine months, and attrition spikes every time a competing market (Australia, Canada, or the UK) loosens its immigration settings. TERN's platform targets that friction point: using AI to source, credential-verify, deploy, and monitor clinical staff at a speed and scale that traditional healthcare recruitment firms cannot match.

For hospital CEOs and HR directors, the core bet is that AI can compress the credentialing and onboarding pipeline from weeks to days, and that cutting time-to-deployment for a single specialist by even one week pays back the cost of an annual platform licence. A locum specialist in Dubai commands AED 3,000 to AED 6,000 per shift, so even marginal efficiency gains carry material P&L impact.

Regulatory backdrop and the credentialing question

Clinical AI platforms operating in the UAE face a layered compliance environment. Any tool that touches licensing, scope-of-practice, or clinical deployment decisions falls under DHA jurisdiction in Dubai, the Department of Health Abu Dhabi (DOH) in the capital, and the Ministry of Health and Prevention (MOHAP) across the Northern Emirates. None of the three authorities has published a formal framework specifically governing AI systems that make or inform credentialing decisions, a regulatory gap that creates both opportunity and legal uncertainty for TERN.

The DOH's AI and Digital Health Strategy 2025–2030 commits Abu Dhabi to AI-driven workforce planning tools at the emirate level, which suggests regulatory appetite for what TERN is building. Appetite and a clear compliance pathway are different things, however. Hospitals that adopt the platform early will need their legal and compliance teams to map TERN's outputs against existing DHA and DOH licensing rules, particularly around who bears liability when an AI-matched clinician is placed in a role and an adverse event occurs.

• DHA governs Dubai: clinician licensing, scope approvals, facility accreditation
• DOH governs Abu Dhabi and Al Ain: separate licensing track, different fee schedule
• MOHAP governs Sharjah, Ajman, RAK, UAQ, Fujairah: unified federal framework
• No cross-emirate clinical AI credentialing standard exists as of Q3 2025

What operators should watch

The $33 million gives TERN roughly two to three years of runway at an aggressive GCC expansion pace, assuming burn rates typical for a platform-stage health-tech company. Expect the company to target large hospital groups first — Mediclinic Middle East, NMC Health's successor entities, and government health systems in Abu Dhabi and Dubai — where workforce volumes are large enough to generate the placement data the AI model needs to improve. Smaller private clinics and polyclinics will likely come later, once the platform has a verified track record in high-volume settings.

For health-tech founders watching this raise: investor appetite for clinical workforce AI is real, but the defensible moat will be the credentialing data layer, not the AI model itself. Any company that builds a proprietary, GCC-verified dataset of clinician credentials, competencies, and placement outcomes will be hard to replicate. That is what TERN is buying time to build.